Iron-chelating therapy with the new oral agent ICL670 (Exjade).

@article{Cappellini2005IronchelatingTW,
  title={Iron-chelating therapy with the new oral agent ICL670 (Exjade).},
  author={Maria Domenica Cappellini},
  journal={Best practice & research. Clinical haematology},
  year={2005},
  volume={18 2},
  pages={289-98}
}
Iron-chelation therapy is essential in iron-overloaded patients. The long-term efficacy of this approach has been demonstrated unequivocally with deferoxamine, which effectively controls iron concentrations, thereby limiting organ damage and preventing premature death. However, as deferoxamine is administered parenterally, poor compliance is a significant limitation to successful patient management. ICL670 (Exjade) is a highly efficient and selective oral iron chelator. The results of phase I… CONTINUE READING